Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
Aishath Naeem(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Yue Ren(Dana-Farber Cancer Institute), Stacey M. Fernandes(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), Mauno Vihinen(Lund University), Raquel A. Jacobs(Broad Institute), Laxmi Parida(IBM (United States)), Annette S. Kim, Justin Cha(Broad Institute), Smith Rjh(Karolinska University Hospital), James A. Lederer(Brigham and Women's Hospital), Brian P. Danysh(Broad Institute), Gordon Saksena, Chaya Levovitz(IBM (United States)), Ignaty Leshchiner(Broad Institute), Kara Slowik(Broad Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Rula Zain(Karolinska University Hospital), Filippo Utro(IBM (United States)), Yinglu Zhou(Dana-Farber Cancer Institute), Stephen P. Martindale(Harvard University), Gad Getz(Broad Institute), Qing Wang(New Hope Liuhe (China)), Kahn Rhrissorrakrai(IBM (United States))
Cited by 79
Related Papers
Integrative genomics viewer
|Nature Biotechnology|2011|16.5k